Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of demcizumab added to gemcitabine + Abraxane in first-line metastatic pancreatic ductal adenocarcinoma
2014-003355-56Phase 2Completed
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of demcizumab in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (3 arms), sponsored by OncoMed Pharmaceuticals. Primary endpoint: Investigator-assessed progression-free survival. Started Jan 2015; status: completed.
02
Drugs
demcizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2014-003355-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003355-56.